#Germany #Annual Meeting #Hamburg #Evotec SE #Supervisory Board

Evotec Annual General Meeting Results

On June 11, 2026, Evotec SE, a leading life science company specializing in drug discovery and development, shared the results of its Annual General Meeting (AGM) held in Hamburg, Germany. This year’s meeting marked a pivotal moment for the company as shareholders expressed their confidence in the governance of the organization by supporting all proposals put forward during the session.

Election of New Board Members

A significant outcome of the AGM was the successful election of Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Their appointments reflect a strong commitment to effective leadership and governance at Evotec. Following this, the Supervisory Board made a strategic decision by appointing Dieter Weinand as its new Chairman. He takes over from Prof. Dr. Iris Löw-Friedrich, guiding the board towards continued innovation and operational excellence.

Moreover, the re-election of Dr. Duncan McHale and Wesley Wheeler signifies a reinforcement of experienced leadership, ensuring continuity as the company navigates the rapidly evolving landscape of life sciences.

Shareholder Participation

An impressive 43.10% of Evotec’s registered share capital was represented at the AGM, illustrating robust shareholder engagement and involvement in the decision-making processes. The high turnout signals confidence from investors in the direction of the company as it strives to enhance its offerings through innovative research and development strategies.

A Vision for the Future

Evotec prides itself on being at the forefront of drug discovery, merging pioneering science with advanced technologies and a commitment to accessibility. With a vast portfolio of over 100 proprietary R&D assets, the company focuses on crucial therapeutic areas that include oncology, cardiovascular and metabolic diseases, as well as neurology and immunology. Its expertise in small molecules and biologics allows for a comprehensive approach to addressing critical health challenges.

As a life science leader, Evotec collaborates with all Top 20 pharmaceutical companies, alongside thousands of biotech firms, academic institutions, and healthcare stakeholders, demonstrating a flexible partnering model that meets diverse needs.

Insights into Evotec’s Innovations

Evotec is committed to transitioning drug discovery from concept to therapeutic solutions faster and with greater precision. Utilizing proprietary platforms like Molecular Patient Databases, PanOmics, and iPSC-based disease modeling, the company integrates artificial intelligence to redefine the drug development landscape. This initiative aims not only to enhance innovation but also broaden the accessibility of biologics through its subsidiary, Just – Evotec Biologics, which emphasizes quality and affordability in drug manufacturing.

Conclusion

The outcomes of Evotec's AGM indicate a dynamic and promising future for the company. With robust board leadership, strategic governance, and unwavering support from shareholders, Evotec is set to continue its vital role in advancing the frontiers of healthcare and life sciences. For more information on the AGM and further updates, stakeholders are encouraged to visit Evotec’s official website.

For continued insights into the company’s performance and initiatives, follow Evotec on LinkedIn and X/Twitter @Evotec.